醒脑静对急性有机磷农药中毒昏迷患者s100β蛋白的影响及疗效观察  

Observation of influence and curative effect by Xingnaojing on s100β protein in acute organophosphorus pesticide poisoning coma patients

作　　者：陶克奇[1] 蔡阳林[1] 刘之钰[1] 叶镱[1] 关紫云[1] 

机构地区：[1]广东省佛山市南海区人民医院,528200

出　　处：《中国现代药物应用》2016年第3期4-5,共2页Chinese Journal of Modern Drug Application

摘　　要：目的观察醒脑静注射液对急性有机磷农药中毒昏迷患者s100β蛋白的影响及疗效分析。方法 42例有机磷农药中毒昏迷患者,采用随机数字表法将患者分为治疗组和对照组,各21例。对照组采用常规治疗,治疗组在常规治疗的基础上加用醒脑静注射液治疗。观察两组患者昏迷至清醒的时间、胆碱酯酶(CHE)复活时间、中间综合征发生例数,同时在患者昏迷的第1、2、3天分别采取静脉血测定s100β蛋白的含量,并进行分析。结果治疗组患者昏迷至清醒时间、CHE复活时间、中间综合征发生例数明显优于对照组,差异均有统计学意义(P<0.05);s100β蛋白在昏迷第1天两组比较差异无统计学意义(P>0.05),第2、3天两组比较差异均有统计学意义(P<0.05)。结论利用醒脑静注射液治疗有机磷农药中毒昏迷患者,能够明显降低昏迷期间体内s100β蛋白的含量,减少神经功能损害,提高患者的救治率。Objective To observe influence and curative effect by Xingnaojing on s100β protein in acute organophosphorus pesticide poisoning coma patients. Methods A total of 42 acute organophosphorus pesticide poisoning coma patients were divided by random number table into treatment group and control group, with 21 cases in each group. The control group received conventional treatment, and the treatment group received additional Xingnaojing injection. Observation was made on coma to awaken time, revival time of cholinesterase（CHE）, and cases with intermediate syndrome. Contents of s100β protein were detected in the first, second and third days in coma for analysis. Results The treatment group had obviously better coma to awaken time, revival time of CHE, and cases with intermediate syndrome than the control group（P〈0.05）. The difference of s100β protein content had no statistical significance in the first day of coma between the two groups（P〉0.05）. The differences in the second and third days all had statistical significance between the two groups（P〉0.05）. Conclusion Implement of Xingnaojing injection in treating acute organophosphorus pesticide poisoning coma patients can remarkably reduce content of s100β protein and neurological function impairment in coma, and improve cure rate in patients.

关 键 词：醒脑静 急性有机磷农药中毒 昏迷 S100Β蛋白 

分 类 号：R595.4[医药卫生—内科学]